Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
SHSE:600196's PEG Ratio is ranked worse than 81.32% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.65
vs SHSE:600196: 5.29
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Shanghai Fosun Pharmaceutical (Group) Co PEG Ratio Related Terms
Shanghai Fosun Pharmaceutical (Group) Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co PEG Ratio Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co PEG Ratio vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) has a PEG Ratio of 5.29 as of Jul. 14, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. This is 21% above median its historical median of 4.38. Over the past decade, Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio has ranged from 2.06 to 371.94. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #283 out of 348 companies in the Drug Manufacturers industry, placing it in the top 81.3%.
Is Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio too high?
Shanghai Fosun Pharmaceutical (Group) Co's current PEG Ratio of 5.29 is 21% above median its 10-year median of 4.38. Over the past 10 years, this metric has ranged from a low of 2.06 to a high of 371.94. The Drug Manufacturers industry median PEG Ratio is 1.65. Shanghai Fosun Pharmaceutical (Group) Co's value of 5.29 is 220.6% above this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #283 out of 348 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #283 out of 348 companies for PEG Ratio. This places Shanghai Fosun Pharmaceutical (Group) Co in the lower half of its industry. The industry median PEG Ratio is 1.65. Shanghai Fosun Pharmaceutical (Group) Co's value of 5.29 is 220.6% above this benchmark. Historically, Shanghai Fosun Pharmaceutical (Group) Co's own PEG Ratio has ranged from 2.06 to 371.94 over the past decade. While the company's 10-year median is 4.38 vs. the industry median of 1.65, Shanghai Fosun Pharmaceutical (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.65, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current PEG Ratio of 5.29 is 220.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current PEG Ratio is 5.29, which is 21% above median its own 10-year median of 4.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥27.05, compared to a current price of ¥24.05 — trading 11.1% below its estimated fair value. The current PEG Ratio is 5.29, which is 21% above median its 10-year median of 4.38 and 220.6% above the Drug Manufacturers industry median of 1.65. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 78/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196), the current PEG Ratio is 5.29 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of ¥24.05 is trading 11.1% below its estimated GF Value™ of ¥27.05.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600196:
PEG Ratio: 5.29 (21% above median its 10-year median of 4.38)
GF Value™: ¥27.05 vs. price of ¥24.05 (11.1% below fair value)
Industry Position: 220.6% above the Drug Manufacturers median (#283 of 348)
No single metric tells the full story. See the SHSE:600196 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
78GF Score
Get the complete analysis for SHSE:600196
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600196 has been successfully added to your 
